Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 783 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bioequivalence Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02851212
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects

NCT07015671
View directory record Official record
Conditions
Bioequivalence Study in Healthy Subjects, PK/PD
Interventions
10 mg Torsemide tablet, 25 mg Aldactone (Spironolactone) tablet, FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparison of Two Formulations of Androxal

NCT01984398
View directory record Official record
Conditions
Bioequivalence
Interventions
12.5 mg Androxal Formulation A, 12.5 mg Androxal Formulation B, 25 mg Androxal Formulation A, 25 mg Androxal Formulation B
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations

NCT01039584
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
Butoconazole Nitrate Vaginal Cream, Placebo, Gynazole 1 vaginal cream
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions

NCT00759902
View directory record Official record
Conditions
Healthy
Interventions
morphine sulfate extended-release capsules, KADIAN (morphine sulfate extended-release) capsules
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg

NCT00650351
View directory record Official record
Conditions
Healthy
Interventions
Ciprofloxacin Extended-Release Tablets 1000 mg, Cipro® XR Tablets 1000 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg

NCT01020214
View directory record Official record
Conditions
Healthy
Interventions
Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg, Benicar HCT® Tablets 40 mg/25 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

NCT03864666
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Cilostazol 100 mg, PMR 200 mg
Drug
Lead sponsor
Genovate Biotechnology Co., Ltd.,
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Amlodipine 10mg Tablets Under Fed Conditions

NCT00775151
View directory record Official record
Conditions
Healthy
Interventions
amlodipine 10 mg tablet
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg

NCT00649272
View directory record Official record
Conditions
Healthy
Interventions
Oxybutynin Chloride Extended-Release Tablets, 15 mg, Ditropan XL® Extended-release tablets, 15 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg

NCT00649051
View directory record Official record
Conditions
Healthy
Interventions
Metolazone Tablets 2.5 mg, Zaroloxyn® Tablets 2.5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of Testosterone Cypionate in Hypogonadal Males

NCT03792477
View directory record Official record
Conditions
Hypogonadism
Interventions
Test formulation, Reference formulation
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
DeLand, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch

NCT02727205
View directory record Official record
Conditions
Bioequivalence - Irritation and Sensitization Potential of Transdermal Patch
Interventions
Rotigotine Transdermal System
Drug
Lead sponsor
Inflamax Research Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

NCT00648401
View directory record Official record
Conditions
Healthy
Interventions
Verapamil Hydrochloride Extended-Release Capsules, 300 mg, Verelan® PM Extended-Release Capsules, 300 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Benazepril HCl 40 mg Tablets, Fed

NCT00836537
View directory record Official record
Conditions
Healthy
Interventions
Benazepril HCl 40 mg Tablets, Lotensin® 40 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

NCT00944346
View directory record Official record
Conditions
Healthy
Interventions
Metformin HCl
Drug
Lead sponsor
Torrent Pharmaceuticals Limited
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 23, 2009 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers

NCT02074553
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ro542-4802/F03 (Reference), Ro542-4802/F07 (Test), Ro542-4802/F08 (Test), Ro542-4802/F14 (Test)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lesinurad Tablet Bioequivalence

NCT02127775
View directory record Official record
Conditions
Healthy
Interventions
Lesinurad 400 mg (manufactured at Site 1), Lesinurad 400 mg (manufactured at Site 2)
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.

NCT01182194
View directory record Official record
Conditions
Healthy
Interventions
Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following A Low, Medium, And High-Fat Evening Meal As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers

NCT01257529
View directory record Official record
Conditions
Healthy
Interventions
Pregabalin controlled release, 330 mg, low-fat, Pregabalin controlled release, 330 mg, medium-fat, Pregabalin controlled release, 330 mg, high-fat, Pregabalin immediate release, 300 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels

NCT07253441
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
CTN XR (TBM), CTN SR, CTN XR (Clin)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Lenexa, Kansas • Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions

NCT00776139
View directory record Official record
Conditions
Healthy
Interventions
Cetirizine Hydrochloride 10 mg tablet
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability

NCT00517543
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Rheumatoid Arthritis, Atherosclerosis
Interventions
GW856553
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo

NCT01243450
View directory record Official record
Conditions
Acne
Interventions
Tretinoin, placebo
Drug
Lead sponsor
Spear Pharmaceuticals
Industry
Eligibility
12 Years to 40 Years
Enrollment
958 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Mountain Lakes, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 21, 2026, 1:40 PM EDT